- Home
- AIEV vs IMRN Comparison
AIEV vs IMRN Comparison
Compare AIEV & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIEV
- IMRN
- Stock Information
- Founded
- AIEV 2011
- IMRN 1994
- Country
- AIEV United States
- IMRN Australia
- Employees
- AIEV N/A
- IMRN N/A
- Industry
- AIEV Blank Checks
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- AIEV Finance
- IMRN Health Care
- Exchange
- AIEV Nasdaq
- IMRN Nasdaq
- Market Cap
- AIEV 11.6M
- IMRN 10.1M
- IPO Year
- AIEV N/A
- IMRN N/A
- Fundamental
- Price
- AIEV $0.15
- IMRN $1.80
- Analyst Decision
- AIEV
- IMRN Strong Buy
- Analyst Count
- AIEV 0
- IMRN 1
- Target Price
- AIEV N/A
- IMRN $5.00
- AVG Volume (30 Days)
- AIEV 1.9M
- IMRN 13.7K
- Earning Date
- AIEV 05-15-2025
- IMRN 04-15-2025
- Dividend Yield
- AIEV N/A
- IMRN N/A
- EPS Growth
- AIEV N/A
- IMRN N/A
- EPS
- AIEV N/A
- IMRN N/A
- Revenue
- AIEV N/A
- IMRN $4,048,286.00
- Revenue This Year
- AIEV N/A
- IMRN N/A
- Revenue Next Year
- AIEV N/A
- IMRN N/A
- P/E Ratio
- AIEV N/A
- IMRN N/A
- Revenue Growth
- AIEV N/A
- IMRN 82.90
- 52 Week Low
- AIEV $0.13
- IMRN $1.70
- 52 Week High
- AIEV $12.12
- IMRN $3.09
- Technical
- Relative Strength Index (RSI)
- AIEV N/A
- IMRN 55.96
- Support Level
- AIEV N/A
- IMRN $1.75
- Resistance Level
- AIEV N/A
- IMRN $2.09
- Average True Range (ATR)
- AIEV 0.00
- IMRN 0.13
- MACD
- AIEV 0.00
- IMRN 0.01
- Stochastic Oscillator
- AIEV 0.00
- IMRN 51.28
About AIEV Thunder Power Holdings Inc. Common Stock
Thunder Power Holdings Inc is engaged in the design and development of high-performance electric vehicles.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.